Product Detail
Name :Mary
Whatsapp/wechat:+852 65595853 15227656322
Email:3196678537@.com
Here is an English product overvied for AOD :
Composition:
AOD-9604 (commonly abbreviated as AOD) is a synthetic hexadecapeptide corresponding to amino acid residues 177–191 of human growth hormone, modified with an N‑terminal tyrosine residue to enhance structural stability. Its sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, stabilized by an intramolecular disulfide linkage. With a molecular formula of C₇₈H₁₂₃N₂₃O₂₃S₂ and a molecular weight of approximately 1815 Da, it is produced via solid-phase peptide synthesis and supplied as a high-purity lyophilized powder intended strictly for laboratory research.AOD-9604, abbreviated as AOD, is a synthetic peptide lyophilized powder derived from the terminal fragment of human growth hormone. It only targets fat metabolism, accelerates fat breakdown and inhibits the formation of new fat, enabling fat loss while preserving muscle mass. Unlike intact growth hormone, it barely affects blood glucose and growth-related hormones. It is widely applied in scientific research experiments related to metabolism and body composition, and there are also studies on its cartilage-protecting effects. It is solely intended for use as a raw material in laboratory research.
AOD-9604, often shortened to AOD, is a synthetic peptide raw material developed based on the terminal fragment of growth hormone, with its core function centered on regulating human fat metabolism. It accelerates the catabolism of excess fat in the body while reducing the accumulation of new fat. When reshaping body contours, it can effectively preserve muscle tissue and prevent muscle loss that usually accompanies fat reduction. Compared with full-length growth hormone, this raw material exerts minimal impacts on blood glucose and growth-related endocrine indicators in the body, making it suitable for various research scenarios related to body shape management. In addition, existing relevant studies indicate that it delivers certain beneficial effects on maintaining articular cartilage. This product is only circulated as a laboratory research raw material for in vitro tests and related academic studies, and is not intended for daily physical conditioning. Its storage and handling must comply with professional specifications for experimental raw materials; it should be properly stored away from light and at low temperatures to maintain stable raw material activity.
Mechanism of Action:
AOD-9604 operates independently of the full growth hormone receptor (GHR) and its downstream signaling cascades. It exerts its primary effects on adipose tissue by modulating adrenergic signaling pathways, specifically upregulating cyclic adenosine monophosphate (cAMP) levels within adipocytes. This process enhances the activity of key metabolic enzymes responsible for triglyceride breakdown while concurrently suppressing pathways involved in new fatty acid synthesis, thereby selectively mimicking the lipid-mobilizing domain of human growth hormone without influencing systemic growth factor levels.
Research Advantages:
This compound provides a distinct advantage for metabolic research by isolating the lipolytic functionality of the growth hormone molecule from its anabolic and systemic endocrine effects. Its adipose-selective action allows investigators to study fat metabolism, energy expenditure, and receptor sensitivity in models of obesity or metabolic dysregulation without the confounding variables associated with elevated serum growth factors or impaired glucose homeostasis, making it a precise tool for elucidating metabolic regulatory networks.
Intended Research Population:
AOD-9604 is designated for non-clinical, in vitro, and in vivo investigations involving adipocyte biology, obesity models, lipid metabolism assays, and studies on age-related metabolic decline. It is also utilized in musculoskeletal research exploring cartilage matrix synthesis and joint health. It remains an investigational reference reagent restricted to qualified scientific environments and is not approved for therapeutic, diagnostic, or human/animal administration outside controlled experimental protocols.
Germany
United States
Croatia
South Korea
United Kingdom